Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling

Oncotarget

Volumn 7, Issue 20, 2016, Pages 29492-29506

  Owusu, Benjamin Y ^a   Bansal, Namita ^a   Venukadasula, Phanindra K M ^a   Ross, Larry J ^a   Messick, Troy E ^b   Goel, Sanjay ^c   Galemmo, Robert A ^a   Klampfer, Lidija ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b WISTAR INSTITUTE   (United States)

^c ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

Colon cancer; EGFR; HGF

Indexed keywords

3 [3 [(1 BENZYLPIPERIDIN 4 YL)METHYL] 5 METHYL 2 OXOTETRAHYDROPYRIMIDIN 1(2H)YL]BENZIMIDAMIDE; CETUXIMAB; GEFITINIB; HEPATOCYTE GROWTH FACTOR ACTIVATOR; HEPSIN; JNJ 38877605; MATRIPTASE; PROTEIN KINASE INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZAMIDINE DERIVATIVE; HGF PROTEIN, HUMAN; MET PROTEIN, HUMAN; PRO-HEPATOCYTE GROWTH FACTOR; PROTEIN PRECURSOR; PYRIMIDINONE DERIVATIVE; SRI 31215;

ARTICLE; CANCER RESISTANCE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; DRUG STRUCTURE; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; HUMAN; HUMAN TISSUE; METASTASIS; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; ANTAGONISTS AND INHIBITORS; CANCER ASSOCIATED FIBROBLAST; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZAMIDINES; CANCER-ASSOCIATED FIBROBLASTS; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCYTE GROWTH FACTOR; HUMANS; PROTEIN PRECURSORS; PROTO-ONCOGENE PROTEINS C-MET; PYRIMIDINONES; SIGNAL TRANSDUCTION;

EID: 84969888715     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8785     Document Type: Article

References (69)

1. Weidner KM, Arakaki N, Hartmann G, Vandekerckhove J, Weingart S, Rieder H, Fonatsch C, Tsubouchi H, Hishida T, Daikuhara Y and et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proceedings of the National Academy of Sciences of the United States of America. 1991; 88:7001-7005.
2. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K and Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989; 342:440-443.
3. Comoglio PM, Giordano S and Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature reviews Drug discovery. 2008; 7:504-516.
4. Sierra JR and Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Therapeutic advances in medical oncology. 2011; 3:S21-35.
5. Boccaccio C, Luraghi P and Comoglio PM. MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells. Cancer research. 2014; 74:3647-3651.
6. Luraghi P, Reato G, Cipriano E, Sassi F, Orzan F, Bigatto V, De Bacco F, Menietti E, Han M, Rideout WM, 3rd, Perera T, Bertotti A, Trusolino L, Comoglio PM and Boccaccio C. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer research. 2014; 74:1857-1869.
7. Chong CR and Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nature medicine. 2013; 19:1389-1400.
8. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012; 487:505-509.
9. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012; 487:500-504.
10. Pennacchietti S, Cazzanti M, Bertotti A, Rideout WM, 3rd, Han M, Gyuris J, Perera T, Comoglio PM, Trusolino L and Michieli P. Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. Cancer research. 2014; 74:6598-6609.
11. Vigna E and Comoglio PM. Targeting the oncogenic Met receptor by antibodies and gene therapy. Oncogene. 2014.
12. Seneviratne D, Ma J, Tan X, Kwon YK, Muhammad E, Melhem M, DeFrances MC and Zarnegar R. Genomic instability causes HGF gene activation in colon cancer cells, promoting their resistance to necroptosis. Gastroenterology. 2015; 148:181-191 e117.
13. Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vande Woude G, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nature medicine. 2012; 18:1118-1122.
14. Fukuura T, Miki C, Inoue T, Matsumoto K and Suzuki H. Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma. British journal of cancer. 1998; 78:454-459.
15. Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K and Kusunoki M. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. International journal of cancer. 2009; 125:1657-1662.
16. Toi M, Taniguchi T, Ueno T, Asano M, Funata N, Sekiguchi K, Iwanari H and Tominaga T. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clinical cancer research. 1998; 4:659-664.
17. Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y and Tominaga T. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clinical cancer research. 1995; 1:1031-1034.
18. Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A and Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood. 1998; 91:806-812.
19. Verstovsek S, Kantarjian H, Estey E, Aguayo A, Giles FJ, Manshouri T, Koller C, Estrov Z, Freireich E, Keating M and Albitar M. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia. 2001; 15:1165-1170.
20. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, Resau JH and Vande Woude GF. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer research. 1997; 57:5391-5398.
21. Ferracini R, Di Renzo MF, Scotlandi K, Baldini N, Olivero M, Lollini P, Cremona O, Campanacci M and Comoglio PM. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene. 1995; 10:739-749.
22. Bhowmick NA, Neilson EG and Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004; 432:332-337.
23. Forbs D, Thiel S, Stella MC, Sturzebecher A, Schweinitz A, Steinmetzer T, Sturzebecher J and Uhland K. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. International journal of oncology. 2005; 27:1061-1070.
24. Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T and Austin RJ. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. The Biochemical journal. 2005; 390:125-136.
25. Kataoka H, Hamasuna R, Itoh H, Kitamura N and Koono M. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer research. 2000; 60:6148-6159.
26. Lee SL, Dickson RB and Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. The Journal of biological chemistry. 2000; 275:36720-36725.
27. Owen KA, Qiu D, Alves J, Schumacher AM, Kilpatrick LM, Li J, Harris JL and Ellis V. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membraneassociated protease uPA. The Biochemical journal. 2010; 426:219-228.
28. Parr C, Watkins G, Mansel RE and Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clinical cancer research. 2004; 10:202-211.
29. Szabo R, Rasmussen AL, Moyer AB, Kosa P, Schafer JM, Molinolo AA, Gutkind JS and Bugge TH. c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene. 2011; 30:2003-2016.
30. Kawaguchi M and Kataoka H. Mechanisms of hepatocyte growth factor activation in cancer tissues. Cancers. 2014; 6:1890-1904.
31. Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F and Comoglio PM. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. The Journal of biological chemistry. 1995; 270:603-611.
32. Ye J, Kawaguchi M, Haruyama Y, Kanemaru A, Fukushima T, Yamamoto K, Lin CY and Kataoka H. Loss of hepatocyte growth factor activator inhibitor type 1 participates in metastatic spreading of human pancreatic cancer cells in a mouse orthotopic transplantation model. Cancer science. 2014; 105:44-51.
33. Kawaguchi M, Takeda N, Hoshiko S, Yorita K, Baba T, Sawaguchi A, Nezu Y, Yoshikawa T, Fukushima T and Kataoka H. Membrane-bound serine protease inhibitor HAI-1 is required for maintenance of intestinal epithelial integrity. The American journal of pathology. 2011; 179:1815-1826.
34. Hoshiko S, Kawaguchi M, Fukushima T, Haruyama Y, Yorita K, Tanaka H, Seiki M, Inatsu H, Kitamura K and Kataoka H. Hepatocyte growth factor activator inhibitor type 1 is a suppressor of intestinal tumorigenesis. Cancer research. 2013; 73:2659-2670.
35. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF and Mukhtar H. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer epidemiology, biomarkers & prevention. 2006; 15:217-227.
36. Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H and Sellar GC. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clinical cancer research. 2002; 8:1101-1107.
37. Zeng L, Cao J and Zhang X. Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. WJG. 2005; 11:6202-6207.
38. Nakamura K, Abarzua F, Kodama J, Hongo A, Nasu Y, Kumon H and Hiramatsu Y. Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer. International journal of oncology. 2009; 34:345-353.
39. Hamasuna R, Kataoka H, Meng JY, Itoh H, Moriyama T, Wakisaka S and Koono M. Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: implication for anti-invasive role of HAI-2/PB in glioblastoma cells. International journal of cancer. 2001; 93:339-345.
40. Morris MR, Gentle D, Abdulrahman M, Maina EN, Gupta K, Banks RE, Wiesener MS, Kishida T, Yao M, Teh B, Latif F and Maher ER. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer research. 2005; 65:4598-4606.
41. Kim K, Kim JM, Kim JS, Choi J, Lee YS, Neamati N, Song JS, Heo K and An W. VprBP has intrinsic kinase activity targeting histone H2A and represses gene transcription. Molecular cell. 2013; 52:459-467.
42. Khamas A, Ishikawa T, Shimokawa K, Mogushi K, Iida S, Ishiguro M, Mizushima H, Tanaka H, Uetake H and Sugihara K. Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2'-deoxycytidine, microarray and gene expression profile. Cancer genomics & proteomics. 2012; 9:67-75.
43. Wood RJ, Tchack L, Angelo G, Pratt RE and Sonna LA. DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiological genomics. 2004; 17:122-129.
44. Galemmo RA, Jr., Maduskuie TP, Dominguez C, Rossi KA, Knabb RM, Wexler RR and Stouten PF. The de novo design and synthesis of cyclic urea inhibitors of factor Xa: initial SAR studies. Bioorganic & medicinal chemistry letters. 1998; 8:2705-2710.
45. Galemmo RA, Jr., Wells BL, Rossi KA, Alexander RS, Dominguez C, Maduskuie TP, Stouten PF, Wright MR, Aungst BJ, Wong PC, Knabb RM and Wexler RR. The de novo design and synthesis of cyclic urea inhibitors of factor Xa: optimization of the S4 ligand. Bioorganic & medicinal chemistry letters. 2000; 10:301-304.
46. Venukadasula PKM OB, Bansal N, Ross LJ, Hobrath JV, Bao D, Truss JW, Stackhouse M, Messick TE, Klampfer L, and Galemmo RA. Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation. ACS Med Chem Lett. 2016; 7:177-181.
47. Lokker NA, Mark MR, Luis EA, Bennett GL, Robbins KA, Baker JB and Godowski PJ. Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. The EMBO journal. 1992; 11:2503-2510.
48. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G and Medema JP. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature cell biology. 2010; 12:468-476.
49. Weidner KM, Behrens J, Vandekerckhove J and Birchmeier W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. The Journal of cell biology. 1990; 111:2097-2108.
50. Fram ST, Wells CM and Jones GE. HGF-induced DU145 cell scatter assay. Methods in molecular biology. 2011; 769:31-40.
51. Song N, Liu S, Zhang J, Liu J, Xu L, Liu Y and Qu X. Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells. International journal of molecular sciences. 2014; 15:5838-5851.
52. Goel S, Huang J and Klampfer L. K-Ras, Intestinal Homeostasis and Colon Cancer. Current clinical pharmacology. 2013. 53.
53. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F and Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer research. 2006; 66:3992-3995.
54. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore- Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010; 304:1812-1820.
55. Takahashi N, Yamada Y, Furuta K, Honma Y, Iwasa S, Takashima A, Kato K, Hamaguchi T and Shimada Y. Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. British journal of cancer. 2014; 110:2716-2727.
56. Klemm F and Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends in cell biology. 2015; 25:198-213.
57. Junttila MR and de Sauvage FJ. Influence of tumour microenvironment heterogeneity on therapeutic response. Nature. 2013; 501:346-354.
58. Cunningham MP, Thomas H, Fan Z and Modjtahedi H. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cancer research. 2006; 66:7708-7715.
59. Gherardi E, Birchmeier W, Birchmeier C and Vande Woude G. Targeting MET in cancer: rationale and progress. Nature reviews Cancer. 2012; 12:89-103.
60. Kataoka H, Shimomura T, Kawaguchi T, Hamasuna R, Itoh H, Kitamura N, Miyazawa K and Koono M. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. The Journal of biological chemistry. 2000; 275:40453-40462.
61. Han Z, Harris PK, Jones DE, Chugani R, Kim T, Agarwal M, Shen W, Wildman SA and Janetka JW. Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer. ACS medicinal chemistry letters. 2014; 5:1219-1224.
62. Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM and Michieli P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. The Journal of clinical investigation. 2004; 114:1418-1432.
63. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD and Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of clinical oncology. 2008; 26:1626-1634.
64. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ and Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England journal of medicine. 2008; 359:1757-1765.
65. Kalluri R and Zeisberg M. Fibroblasts in cancer. Nature reviews Cancer. 2006; 6:392-401.
66. Han Z, Harris PK, Karmakar P, Kim T, Owusu BY, Wildman SA, Klampfer L and Janetka JW. alpha- Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer. ChemMedChem. 2016.
67. Michieli P, Basilico C, Pennacchietti S, Maffe A, Tamagnone L, Giordano S, Bardelli A and Comoglio PM. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene. 1999; 18:5221-5231.
68. Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, Pachlewski J, Oledzki J and Ostrowski J. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PloS one. 2010; 5.
69. Gaedcke J, Grade M, Jung K, Camps J, Jo P, Emons G, Gehoff A, Sax U, Schirmer M, Becker H, Beissbarth T, Ried T and Ghadimi BM. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes, chromosomes & cancer. 2010; 49:1024-1034.